Thomas Shrader, PhD, CFA

Contact Us

Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Prior to BTIG, Mr. Shrader was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.


Coverage Area

Company Ticker
MacroGenics, Inc. MGNX
Precision BioSciences, Inc. DTIL
Biogen, Inc. BIIB
Denali Therapeutics Inc. DNLI
Esperion Therapeutics, Inc. ESPR
Gritstone bio GRTS
G1 Therapeutics, Inc. GTHX
Arcus Biosciences, Inc. RCUS
Seagen Inc. SGEN
Synlogic, Inc. SYBX
Verona Pharma plc VRNA
Xencor, Inc. XNCR
Cue Biopharma, Inc. CUE
Alector Inc. ALEC
Stoke Therapeutics, Inc. STOK
Mersana Therapeutics MRSN
BridgeBio Pharma, Inc. BBIO
Minerva Neurosciences, Inc. NERV
Checkmate Pharmaceuticals CMPI
INmune Bio Inc. INMB
Aldeyra Therapeutics ALDX
Silence Therapeutics SLN
Replimune Group, Inc. REPL
SQZ Biotechnologies Co SQZ
BioAtla BCAB
Nuvation Bio NUVB
OncoSec Medical ONCS
Pliant Therapeutics PLRX
Celularity CELU
Gain Therapeutics, Inc. GANX